Rescuing COX-2 inhibitors from the waste bin.
Albini
Adriana
A
Noonan
Douglas M
DM
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000925:Anticoagulants / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000378:metabolism; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects; D011720:Pyrazoles / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D000096926:Benzenesulfonamides
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D011720:Pyrazoles; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; C406224:valdecoxib; D000096926:Benzenesulfonamides